TL;DR: KPV (lysine-proline-valine) is a three-amino-acid tripeptide corresponding to the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). In preclinical research, primarily in vitro and murine colitis models, KPV has been documented to inhibit NF-κB and MAP kinase inflammatory signaling pathways, and to enter intestinal epithelial and immune cells via the oligopeptide transporter PepT1. The research base is predominantly preclinical. KPV is not FDA approved, not approved for human use, and represents an early-stage area of basic research investigation.
Research-Use Disclaimer: This article is for educational and research reference purposes only. KPV is a research compound, not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical research. For adults 21+ with a research interest only.
What Is KPV? Definition and Structural Identity
KPV is a tripeptide, a chain of three amino acids, with the sequence Lys-Pro-Val (lysine-proline-valine). Its significance in the research literature derives from its structural relationship to alpha-melanocyte-stimulating hormone (α-MSH): KPV constitutes the C-terminal three residues (positions 11–13) of this 13-amino-acid neuropeptide hormone.
Alpha-MSH is itself derived from the precursor protein proopiomelanocortin (POMC) by post-translational processing. The full α-MSH hormone exerts anti-inflammatory effects through binding to melanocortin receptors (MC1R through MC5R), which are expressed across immune system cells, skin, and nervous tissue. KPV, being only the terminal fragment, lacks the sequence motif required to bind classical melanocortin receptors, yet published preclinical research has documented that it retains substantial anti-inflammatory activity through distinct mechanisms.
In the research literature, this fragment is sometimes identified as α-MSH(11–13). The absence of melanocortin receptor binding is a defining feature that separates its research profile from that of the full α-MSH molecule, including the absence of pigmentary (melanogenic) effects that limit the clinical development of the full hormone.
What Anti-Inflammatory Mechanisms Has KPV Research Documented?
Based on articles retrieved from PubMed, preclinical research has proposed and examined several mechanistic pathways through which KPV exerts anti-inflammatory effects in experimental models. The most consistently documented are summarized below.
1. NF-κB and MAP Kinase Pathway Inhibition
The most detailed mechanistic investigation of KPV published to date is a 2008 study by Dalmasso, Charrier-Hisamuddin, Nguyen, Yan, Sitaraman, and Merlin in Gastroenterology. Using human intestinal epithelial cell lines (Caco2-BBE, HT29-Cl.19A) and human T cells (Jurkat) stimulated with pro-inflammatory cytokines, the researchers found that nanomolar concentrations of KPV inhibited NF-κB activation and MAP kinase inflammatory signaling pathways, and reduced pro-inflammatory cytokine secretion. The NF-κB inhibition was assessed via luciferase gene reporter, Western blot, and real-time RT-PCR. This study (PMID 18061177) established the core mechanistic framework that subsequent KPV research has built upon.
2. PepT1-Mediated Cellular Uptake in the Gut
The same 2008 Gastroenterology study by Dalmasso et al. also characterized the cellular entry mechanism for KPV in intestinal tissue. The investigators used radiolabeled substrate competition and [³H]KPV uptake kinetic experiments to demonstrate that KPV enters intestinal epithelial and immune cells via PepT1, the oligopeptide transporter (SLC15A1) that is normally expressed in the small intestine and is upregulated in the colon during inflammatory bowel disease. This transporter-mediated uptake mechanism is significant because PepT1 overexpression in inflamed colonic tissue may concentrate KPV specifically at sites of active inflammation.
The diagnostic relevance of PepT1-KPV interaction was further confirmed in a 2017 study by Zeng et al. in ACS Applied Materials & Interfaces, which developed a fluorescent probe (DCM-KPV) exploiting PepT1’s selectivity for KPV to visualize and distinguish between chronic and acute ulcerative colitis in cell and animal models. The probe’s specificity confirmed that KPV’s accumulation in colonic tissue is transporter-dependent (PMID 28349696).
3. Efficacy in Murine Colitis Models
Following the mechanistic work, Dalmasso et al. (2008) reported that oral administration of KPV in drinking water reduced the incidence of both DSS-induced and TNBS-induced colitis in mice, as assessed by histologic scoring and pro-inflammatory cytokine mRNA expression. These are two well-characterized rodent models used to study intestinal inflammation; findings from these models are considered preclinical data and do not constitute clinical evidence for use in human inflammatory bowel disease.
4. Nanoparticle Delivery Enhances Efficacy in Murine Models
A 2010 study by Laroui, Dalmasso, Nguyen, Yan, Sitaraman, and Merlin in Gastroenterology explored whether encapsulating KPV in targeted nanoparticles could improve delivery to inflamed colonic tissue. Using a polysaccharide hydrogel system (alginate-chitosan) to encapsulate KPV-loaded nanoparticles, the researchers found that NP-KPV reduced inflammatory parameters in the DSS-induced colitis mouse model at a concentration 12, 000-fold lower than that required for free KPV in solution to achieve similar efficacy (PMID 19909746). This concentration differential was attributed to enhanced delivery precision to the colonic mucosa rather than to increased potency of the compound itself.
5. Role of PepT1 in Colitis-Associated Tumorigenesis Research
A 2016 study by Viennois, Ingersoll, Ayyadurai, Zhao, Wang, Zhang, Han, Garg, Xiao, and Merlin in Cellular and Molecular Gastroenterology and Hepatology investigated the role of PepT1 in colitis-associated cancer (CAC) using transgenic mice overexpressing human PepT1 in intestinal epithelial cells and PepT1-knockout mice. The study found that administration of KPV prevented carcinogenesis in wild-type mice subjected to AOM/DSS treatment, but this inhibitory effect was absent in PepT1-knockout mice, confirming that KPV’s anti-inflammatory activity in these colitis models is transporter-dependent (PMID 27458604). Human colonic biopsy analysis in the same study detected increased PepT1 expression in colorectal cancer tissue, which the authors noted as a potential future target. This is a research observation and does not constitute clinical evidence for any therapeutic application.
6. Anti-Inflammatory Activity Independent of Melanocortin Receptors
Two reviews in the broader α-MSH literature have characterized the mechanistic separation between the full hormone and its KPV fragment. A 2007 review by Luger and Brzoska in Annals of the Rheumatic Diseases documented that most of the anti-inflammatory activities of α-MSH can be attributed to its C-terminal tripeptide KPV, which lacks the sequence motif for melanocortin receptor binding yet modulates NF-κB activation, adhesion molecule expression, pro-inflammatory cytokine production, and inflammatory cell migration (PMID 17934097). A 2010 review by Brzoska, Böhm, Lügering, Loser, and Luger in Advances in Experimental Medicine and Biology further characterized KPV and the related tripeptide KdPT as promising candidates for anti-inflammatory peptide therapy on the basis of their receptor-independent signaling, lack of pigmentary activity, and favorable physicochemical properties in preclinical frameworks (PMID 21222263).
7. Neuroprotective Context: α-MSH(11–13) in Traumatic Brain Injury Models
A 2013 study by Schaible et al. in PLoS One investigated the KPV-equivalent fragment α-MSH(11–13) in a controlled cortical impact (CCI) mouse model of traumatic brain injury. A single intraperitoneal administration of 1 mg/kg resulted in reduced secondary lesion volume, reduced microglia activation, and reduced neuronal apoptosis compared to controls (PMID 23940690). The authors noted increased MC1R expression in the injured brain tissue over the 48-hour post-injury window and proposed that neuroprotection may involve partial MC1R engagement in the CNS injury context, even for the short fragment. This study represents a separate research context from the intestinal inflammation literature and underscores that KPV/α-MSH(11–13) has been studied across multiple preclinical inflammation models.
What Is KPV’s Evidence Tier? An Honest Assessment
Accurate representation of the evidence state for KPV requires acknowledging that the published research is almost entirely preclinical. The table below summarizes the landscape:
| Evidence Level | Status for KPV (as of 2026) |
|---|---|
| Human randomized controlled trials | Not available; no published human RCTs for KPV |
| Peer-reviewed animal model studies | Present, primarily DSS- and TNBS-induced murine colitis models; TBI mouse model |
| In vitro / cell culture evidence | Consistent, multiple intestinal epithelial cell lines; human T cells; mechanistic data for NF-κB and MAP kinase inhibition |
| Delivery / formulation research | Active, nanoparticle and hydrogel delivery systems studied in preclinical settings |
| FDA approval status | Not approved for any human use |
| Evidence tier (Legendary Labz framework) | Tier 3: robust preclinical data; no human RCT evidence |
The critical limitation to state plainly: In vitro cell culture results and murine colitis models, even well-designed ones, do not predict human efficacy or safety. Rodent intestinal physiology, transporter expression profiles, and immune responses differ meaningfully from those in humans. The KPV research base is noteworthy for its internal mechanistic consistency and cross-model replication at the preclinical level, but the complete absence of human clinical trial data means its efficacy and safety profile in humans is scientifically unestablished.
What Is KPV’s Regulatory and Research Status?
FDA (United States)
KPV is not approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. It has not entered late-stage clinical trials and has no approved indication, no authorized human dosing protocol, and no regulatory pathway established as of 2026. Researchers should consult current FDA guidance directly for the most current status.
Research Classification
KPV is a preclinical research compound. Its published literature is primarily from academic gastroenterology, immunology, and pharmacology groups studying intestinal inflammation and peptide delivery mechanisms. It does not appear on the WADA Prohibited List by name; however, compounds with unapproved status are subject to WADA’s Section S0 provisions for athletes.
Frequently Asked Questions About KPV
What is KPV peptide?
KPV is a tripeptide with the sequence lysine-proline-valine (Lys-Pro-Val), corresponding to the C-terminal three residues (positions 11–13) of alpha-melanocyte-stimulating hormone (α-MSH). Derived from the larger POMC precursor protein, KPV is studied in preclinical models for anti-inflammatory properties that do not require binding to classical melanocortin receptors.
Is KPV FDA approved?
No. KPV is not approved by the FDA for any therapeutic use in humans. It is a research compound studied in in vitro and murine models. It has no approved indication, no authorized human dosing protocol, and is not legally available as a drug or dietary supplement in the United States.
How does KPV’s anti-inflammatory mechanism work?
Based on preclinical research, KPV has been documented to inhibit NF-κB activation and MAP kinase signaling in intestinal epithelial and immune cell models at nanomolar concentrations, reducing pro-inflammatory cytokine secretion. Cellular uptake in gut tissue is mediated by the oligopeptide transporter PepT1, which is overexpressed in inflamed colonic tissue. These are in vitro and animal model findings; human mechanistic data is not established.
What is KPV’s evidence tier for research?
Research use only. Not intended for human use. Not FDA approved. This article documents published scientific literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources, read them in full. Study findings in murine and cell culture models do not represent expected outcomes in humans. Must be 21+.